Medical applications of microarray technologies: A regulatory science perspective

Emanuel F. Petricoin*, Joseph L. Hackett, Lawrence J. Lesko, Raj K. Puri, Steven I. Gutman, Konstantin Chumakov, Janet Woodcock, David W. Feigal, Kathryn C. Zoon, Frank D. Sistare

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

210 Scopus citations


The potential medical applications of microarrays have generated much excitement, and some skepticism, within the biomedical community. Some researchers have suggested that within the decade microarrays will be routinely used in the selection, assessment, and quality control of the best drugs for pharmaceutical development, as well as for disease diagnosis and for monitoring desired and adverse outcomes of therapeutic interventions. Realizing this potential will be a challenge for the whole scientific community, as breakthroughs that show great promise at the bench often fail to meet the requirements of clinicians and regulatory scientists. The development of a coop­erative framework among regulators, product sponsors, and technology experts will be essential for realizing the revolutionary promise that microarrays hold for drug development, regulatory science, medical practice and pub­lic health.

Original languageEnglish
Pages (from-to)474-479
Number of pages6
JournalNature Genetics
Issue number4S
StatePublished - Dec 2002
Externally publishedYes


Dive into the research topics of 'Medical applications of microarray technologies: A regulatory science perspective'. Together they form a unique fingerprint.

Cite this